Business Context and Reporting Period
This Form 8-K filing by Sunshine Heart, Inc. (not Nuwellis, Inc.) covers events occurring on November 30, 2015. The report details significant changes in executive leadership, specifically the departure of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation and separation costs:
- CEO Separation Lump Sum: $357,075 (equal to annual base salary).
- CEO Assumed Bonus: $142,830 (full-year target bonus for 2015).
- Interim CEO Retainer: $26,250 per month.
- Health Insurance: Company to pay 100% of COBRA premiums for 12 months for the departing CEO.
Material Changes
The primary material change is the departure of David A. Rosa as Chief Executive Officer, President, and Director, effective November 30, 2015. Concurrently, the Board appointed John L. Erb as Interim Chief Executive Officer and President, effective November 23, 2015. Mr. Erb will continue as Chairman of the Board and devote approximately 60% of his time to the role. Board committee assignments were adjusted to accommodate Mr. Erb's new role, with Gregory D. Waller replacing him on the Compensation Committee and Paul R. Buckman replacing him on the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The separation agreement notes that benefits are consistent with those Mr. Rosa would have received had he been terminated without cause. The company is obligated to use commercially reasonable efforts to maintain Mr. Rosa's coverage under existing officer insurance policies.
Investor Verification Checklist
- Verify the total immediate cash outflow for the CEO separation ($500,000 approx. in salary and bonus).
- Confirm the duration and cost of the interim CEO arrangement ($26,250/month).
- Review the attached Separation Agreement (Exhibit 99.1) for specific vesting acceleration terms on equity awards.
- Assess the impact of the CEO departure on ongoing clinical trials or product development timelines, as not detailed in this summary.